NO₂ Formation
NO can react with oxygen to form nitrogen dioxide, which may irritate and injure respiratory tissue. Inspired NO₂ concentrations must be monitored.
Home | Site Map | Contact Us
Views: 108 Author: James Publish Time: 2026-10-26 Origin: Site
Clinical Applications, Delivery Systems & Safety in Modern Hospitals
Understanding inhaled nitric oxide therapy and the equipment, monitoring, and infrastructure considerations behind its responsible use.
NO · Nitric oxide Medical nitric oxide (NO) is a specialized therapeutic gas used in selected critical-care settings to support pulmonary circulation and improve oxygenation.
Unlike conventional medical gases such as oxygen and medical air, inhaled nitric oxide (iNO) acts as a selective pulmonary vasodilator, helping relax blood vessels in ventilated regions of the lungs. As hospitals expand neonatal and other specialized critical-care services, safe NO therapy requires coordinated planning across clinical care, biomedical engineering, respiratory therapy, and procurement.
Nitric oxide is a colorless gas with the chemical formula NO . The human body naturally produces nitric oxide as a signaling molecule involved in vascular relaxation and other physiological processes. When delivered through an appropriate inhalation system, NO activates pathways that relax pulmonary vascular smooth muscle and can decrease pulmonary vascular resistance.
Inhaled nitric oxide is rapidly inactivated after entering the bloodstream, so its vasodilatory effects are predominantly confined to the lungs. This is one reason it is distinguished from systemic vasodilator treatments.
Nitric oxide; inhaled pulmonary vasodilator.
Nitrous oxide; a different gas used for anesthesia and analgesia.
Nitrogen dioxide; a harmful by-product that must be monitored.
One well-established use of inhaled NO is in term and near-term newborns with hypoxic respiratory failure associated with pulmonary hypertension. In the United States, approved INOmax labeling specifies term and near-term neonates over 34 weeks’ gestation with clinical or echocardiographic evidence of pulmonary hypertension, together with ventilatory support and other appropriate care.
In eligible patients, iNO can improve oxygenation and reduce the need for extracorporeal membrane oxygenation (ECMO).
Clinicians may also consider iNO in selected pulmonary hypertensive crises or perioperative cardiac care. Such uses depend on specialist judgment, local guidance, and country-specific regulatory status; they should not be interpreted as universal approved indications.
A specialized delivery system introduces a precisely controlled concentration of nitric oxide into a compatible breathing circuit. Nitric oxide may be supplied from qualified medical-gas cylinders or, in some approved technologies, generated by dedicated equipment at the point of care.
A complete clinical configuration may incorporate:
All components must be selected and operated according to their intended use and the relevant manufacturer's instructions.
The therapeutic role of nitric oxide does not eliminate its risks. Delivery systems require continuous monitoring and trained clinical oversight.
NO can react with oxygen to form nitrogen dioxide, which may irritate and injure respiratory tissue. Inspired NO₂ concentrations must be monitored.
Excess nitric oxide exposure can elevate methemoglobin and interfere with oxygen transport. Clinical blood monitoring is necessary.
Abrupt discontinuation may worsen oxygenation and increase pulmonary artery pressure; weaning requires appropriate clinical management.
Accurate dosing, compatible equipment, monitoring, alarms and contingency planning are essential to a safe therapy program.
Inhaled NO must be administered by trained professionals using an approved, calibrated system under applicable product labeling and institutional protocols. This article does not provide treatment instructions or dosing recommendations.
NO therapy is not a routine extension of a standard hospital oxygen or medical-air pipeline. It calls for a dedicated, validated therapeutic delivery approach and a coordinated operational plan.
| Planning area | Key considerations |
|---|---|
| Clinical environment | NICU / critical-care workflow, trained teams and patient monitoring |
| Delivery equipment | Approved device and respiratory equipment compatibility |
| Gas supply | Qualified source, secure handling, appropriate inventory and backups |
| Safety & monitoring | NO, NO₂, O₂ measurements, alarms and methemoglobin monitoring |
| Procurement & support | Regulatory approval, commissioning, service, calibration and training |
Traditional therapies commonly rely on specially prepared cylinders with controlled NO delivery hardware. Point-of-care generation technologies represent another delivery approach, where authorized for use. Equipment evaluation should consider approved indications, reliability, safety controls, lifecycle cost, clinical workflow and technical support—not simply the availability of the gas itself.
Importantly, the term medical nitric oxide system can refer to the drug or gas source, the administration equipment, or an integrated therapy platform. These are not interchangeable procurement categories.
Medical nitric oxide has an established role in eligible newborns with hypoxic respiratory failure associated with pulmonary hypertension and may be considered for other selected specialist applications. Effective use depends on appropriate patient selection, precise administration, vigilant monitoring, and trained care teams.
For modern hospitals, planning for iNO therapy requires alignment between clinical objectives, device compatibility, safety procedures and equipment support.